trimetazidine has been researched along with Obesity in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Dun, Y; Fu, S; Li, C; Liu, S; Qi, D; Qiu, L; Ripley-Gonzalez, JW; You, B; Zhang, W; Zheng, F | 1 |
| Fillmore, N; Ilkayeva, OR; Jaswal, JS; Keung, W; Koves, TR; Lopaschuk, DG; Lopaschuk, GD; Mori, J; Muoio, DM; Ussher, JR; Wagg, CS; Zhang, L | 1 |
| Beker, DL; Fillmore, N; Jaswal, JS; Keung, W; Lopaschuk, GD; Mori, J; Ussher, JR; Wagg, CS | 1 |
| Shao, XH; Song, GY; Teng, SY; Wu, YJ; Yao, J; Zhao, ZY | 1 |
| Borra, R; Bucci, M; Del Ry, S; Giannessi, D; Iozzo, P; Knuuti, J; Maggio, R; Någren, K; Nuutila, P; Oikonen, V; Parkkola, R; Rigazio, S; Taittonen, M; Tuunanen, H; Viljanen, T | 1 |
| Borra, R; Bucci, M; Cabiati, M; Del Ry, S; Iozzo, P; Knuuti, J; Maggio, R; Någren, K; Nuutila, P; Opie, LH; Pagotto, U; Pärkkä, JP; Parkkola, R; Rigazio, S; Taittonen, M; Tuunanen, H; Viljanen, T | 1 |
| Ben Mosbah, I; Casillas-Ramírez, A; Peralta, C; Roselló-Catafau, J; Serafín, A; Xaus, C | 1 |
1 trial(s) available for trimetazidine and Obesity
| Article | Year |
|---|---|
Human obesity is characterized by defective fat storage and enhanced muscle fatty acid oxidation, and trimetazidine gradually counteracts these abnormalities.
Topics: Adult; Aged; Anti-Obesity Agents; Cross-Sectional Studies; Fats; Fatty Acids; Fluorodeoxyglucose F18; Humans; Lipid Metabolism; Middle Aged; Muscle, Skeletal; Obesity; Oxidation-Reduction; Positron-Emission Tomography; Trimetazidine; Up-Regulation; Vasodilator Agents; Young Adult | 2011 |
6 other study(ies) available for trimetazidine and Obesity
| Article | Year |
|---|---|
Trimetazidine and exercise provide comparable improvements to high fat diet-induced muscle dysfunction through enhancement of mitochondrial quality control.
Topics: Animals; Cell Line; Combined Modality Therapy; Diet, High-Fat; Disease Models, Animal; Humans; Lipid Metabolism; Male; Mice; Mitochondria; Muscle, Skeletal; Muscular Atrophy; Myoblasts; Obesity; Oxidation-Reduction; Palmitic Acid; Physical Conditioning, Animal; Trimetazidine | 2021 |
Treatment with the 3-ketoacyl-CoA thiolase inhibitor trimetazidine does not exacerbate whole-body insulin resistance in obese mice.
Topics: Acetyl-CoA C-Acyltransferase; Angina Pectoris; Animals; Cells, Cultured; Diet, High-Fat; Fatty Acids; Glucose Tolerance Test; Insulin; Insulin Resistance; Lipid Metabolism; Mice; Mice, Inbred C57BL; Muscle Fibers, Skeletal; Myocytes, Cardiac; Obesity; Oxidation-Reduction; Rats; Trimetazidine; Vasodilator Agents | 2014 |
Trimetazidine therapy prevents obesity-induced cardiomyopathy in mice.
Topics: Acetyl-CoA C-Acyltransferase; Animals; Cardiomyopathies; Echocardiography; Heart Ventricles; Hypertrophy, Left Ventricular; Male; Mice; Mice, Inbred C57BL; Obesity; Oxidation-Reduction; Palmitates; Trimetazidine; Vasodilator Agents | 2014 |
The expression of Ubc9 and the intensity of SERCA2a-SUMOylation were reduced in diet-induced obese rats and partially restored by trimetazidine.
Topics: Animals; Disease Models, Animal; Male; Myocytes, Cardiac; Obesity; Palmitic Acid; Rats; Rats, Sprague-Dawley; RNA, Messenger; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Sumoylation; Trimetazidine; Ubiquitin-Conjugating Enzymes | 2015 |
Trimetazidine reduces endogenous free fatty acid oxidation and improves myocardial efficiency in obese humans.
Topics: Adult; Aged; Body Mass Index; Fatty Acids, Nonesterified; Female; Glucose; Heart Function Tests; Hemodynamics; Humans; Lipid Metabolism; Magnetic Resonance Spectroscopy; Male; Middle Aged; Obesity; Palmitates; Positron-Emission Tomography; Trimetazidine; Vasodilator Agents | 2012 |
Trimetazidine: is it a promising drug for use in steatotic grafts?
Topics: Animals; Fatty Liver; Liver Transplantation; Obesity; Rats; Rats, Mutant Strains; Rats, Zucker; Transplantation, Homologous; Trimetazidine; Vasodilator Agents | 2006 |